Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
PHASE2
This is a prospective, randomized phase II trial. The aim of this study is ...
Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial
N/A
The aim of our study is to build up biological, radiological and tissue col...
Status
Not Yet Recruiting
Location
CHU de Rouen
Start Date
2025-09
Trial ID
NCT07034703
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
PHASE2
This is an open-label, phase II study in patients with resectable and borde...